1. Compston, A., A. Coles, et al. 2008. Lancet (London, England) 372 (9648): 1502–1517.

2. Bar-Or, A., E.M. Oliveira, D.E. Anderson, and D.A. Hafler. 1999. Molecular pathogenesis of multiple sclerosis. Journal of Neuroimmunology 100 (1–2): 252–259.

3. Ellwardt, E., and F. Zipp. 2014. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Experimental Neurology 262 Pt A: 8–17.

4. Kebir, H., K. Kreymborg, I. Ifergan, A. Dodelet-Devillers, R. Cayrol, M. Bernard, F. Giuliani, N. Arbour, B. Becher, and A. Prat. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine 13 (10): 1173–1175.

5. Tsuge, M., K. Yasui, T. Ichiyawa, Y. Saito, Y. Nagaoka, M. Yashiro, N. Yamashita, and T. Morishima. 2010 Jul. Increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiology and Immunology. 54 (7): 417–424.

6. Minagar, A., A. Long, T. Ma, T.H. Jackson, R.E. Kelley, D.V. Ostanin, M. Sasaki, A.C. Warren, A. Jawahar, B. Cappell, and J.S. Alexander. 2003. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium: Journal of Endothelial Cell Research 10 (6): 299–307.

7. Yang, F., K. Zhao, X. Zhang, J. Zhang, and B. Xu. 2016. ATP induces disruption of tight junction proteins via IL-1 beta-dependent MMP-9 activation of human blood-brain barrier In Vitro. Neural Plasticity 2016: 8928530.

8. Szabo, S.J., B.M. Sullivan, S.L. Peng, and L.H. Glimcher. 2003. Molecular mechanisms regulating Th1 immune responses. Annual Review of Immunology 21: 713–758.

9. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annual Review of Immunology 23: 683–747.

10. Fletcher, J.M., S.J. Lalor, C.M. Sweeney, N. Tubridy, and K.H. Mills. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology 162 (1): 1–11.

11. Lovett-Racke, A.E., Y. Yang, and M.K. Racke. 2011. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochimica et Biophysica Acta 1812 (2): 246–251.

12. McFarland, H.F., and R. Martin. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nature Immunology 8 (9): 913–919.

13. Markowitz, C.E. 2007. Interferon-beta: mechanism of action and dosing issues. Neurology 68 (24 Suppl 4): S8–S11.

14. Middleton, E., Jr., C. Kandaswami, and T.C. Theoharides. 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacological Reviews 52 (4): 673–751.

15. Gazak, R., D. Walterova, and V. Kren. 2007. Silybin and silymarin--new and emerging applications in medicine. Current Medicinal Chemistry 14 (3): 315–338.

16. Wilasrusmee, C., S. Kittur, G. Shah, J. Siddiqui, D. Bruch, S. Wilasrusmee, et al. 2002. Immunostimulatory effect of Silybum marianum (milk thistle) extract. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 8 (11): Br439–Br443.

17. Gharagozloo, M., E. Velardi, S. Bruscoli, M. Agostini, M. Di Sante, V. Donato, et al. 2010. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacological Research 61 (5): 405–409.

18. Gharagozloo, M., E.N. Javid, A. Rezaei, and K. Mousavizadeh. 2013. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Basic & Clinical Pharmacology & Toxicology. 112 (4): 251–256.

19. Morishima, C., M.C. Shuhart, C.C. Wang, D.M. Paschal, M.C. Apodaca, Y. Liu, et al. 2010. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 138 (2): 671–681 81.e1–2.

20. Kang, J.S., Y.J. Jeon, S.K. Park, K.H. Yang, and H.M. Kim. 2004. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochemical Pharmacology 67 (1): 175–181.

21. Gharagozloo, M., S. Jafari, N. Esmaeil, E.N. Javid, B. Bagherpour, and A. Rezaei. 2013. Immunosuppressive effect of silymarin on mitogen-activated protein kinase signalling pathway: the impact on T cell proliferation and cytokine production. Basic & Clinical Pharmacology & Toxicology. 113 (3): 209–214.

22. Miller, D.H., B.G. Weinshenker, M. Filippi, B.L. Banwell, J.A. Cohen, M.S. Freedman, et al. 2008. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis (Houndmills, Basingstoke, England) 14 (9): 1157–1174.

23. Charil, A., T.A. Yousry, M. Rovaris, F. Barkhof, N. De Stefano, F. Fazekas, et al. 2006. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. The Lancet Neurology 5 (10): 841–852.

24. Kim, E.J., J. Kim, M.Y. Lee, M.S. Sudhanva, S. Devakumar, and Y.J. Jeon. 2014. Silymarin inhibits cytokine-stimulated pancreatic beta cells by blocking the ERK1/2 pathway. Biomolecules & Therapeutics 22 (4): 282–287.

25. Wang, M.J., W.W. Lin, H.L. Chen, Y.H. Chang, H.C. Ou, J.S. Kuo, J.S. Hong, and K.C.G. Jeng. 2002. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. The European Journal of Neuroscience. 16 (11): 2103–2112.

26. Agarwal, C., A. Tyagi, M. Kaur, and R. Agarwal. 2007 Jul. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28 (7): 1463–1470.

27. Grandis, J.R., S.D. Drenning, Q. Zeng, S.C. Watkins, M.F. Melhem, S. Endo, et al. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 97 (8): 4227–4232.

28. Thomson, A.W., H.R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nature Reviews Immunology. 9 (5): 324–337.

29. Weichhart, T., and M.D. Saemann. 2009. The multiple facets of mTOR in immunity. Trends in Immunology. 30 (5): 218–226.

30. Garcia-Maceira, P., and J. Mateo. 2009. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28 (3): 313–324.

31. Reif, K., B.M. Burgering, and D.A. Cantrell. 1997. Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. The Journal of Biological Chemistry 272 (22): 14426–14433.

32. Kim, S., M.G. Choi, H.S. Lee, S.K. Lee, S.H. Kim, W.W. Kim, et al. 2009. Silibinin suppresses TNF-alpha-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway. Molecules (Basel, Switzerland) 14 (11): 4300–4311.

33. Larsen, L., J. Storling, M. Darville, D.L. Eizirik, C. Bonny, N. Billestrup, et al. 2005. Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia 48 (12): 2582–2590.

34. Burke, J.D., L.C. Platanias, and E.N. Fish. 2014. Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3. Journal of Virology 88 (6): 3485–3495.

35. Maino, V.C., M.A. Suni, and J.J. Ruitenberg. 1995. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 20(2):127–133

36. Caruso, A., S. Licenziati, M. Corulli, A.D. Canaris, M.A. De Francesco, S. Fiorentini, et al. 1997. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27 (1): 71–76.

37. Lopez-Cabrera, M., A.G. Santis, E. Fernandez-Ruiz, R. Blacher, F. Esch, P. Sanchez-Mateos, et al. 1993. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. The Journal of Experimental Medicine. 178 (2): 537–547.

38. Hara, T., L.K. Jung, J.M. Bjorndahl, and S.M. Fu. 1986. Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. The Journal of Experimental Medicine. 164 (6): 1988–2005.

39. Bannwart, C.F., E. Nakaira-Takahagi, M.A. Golim, L.T. de Medeiros, M. Romao, I.C. Weel, et al. 2010. Downregulation of nuclear factor-kappa B (NF-kappaB) pathway by silibinin in human monocytes challenged with Paracoccidioides brasiliensis. Life Sciences 86 (23–24): 880–886.

40. Afkarian, M., J.R. Sedy, J. Yang, N.G. Jacobson, N. Cereb, S.Y. Yang, T.L. Murphy, and K.M. Murphy. 2002. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nature Immunology 3 (6): 549–557.

41. Lighvani, A.A., D.M. Frucht, D. Jankovic, H. Yamane, J. Aliberti, B.D. Hissong, B.V. Nguyen, M. Gadina, A. Sher, W.E. Paul, and J.J. O’Shea. 2001. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proceedings of the National Academy of Sciences of the United States of America 98 (26): 15137–15142.

42. Zhu, J., D. Jankovic, A.J. Oler, G. Wei, S. Sharma, G. Hu, L. Guo, R. Yagi, H. Yamane, G. Punkosdy, L. Feigenbaum, K. Zhao, and W.E. Paul. 2012. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37 (4): 660–673.

43. Wei, L., G. Vahedi, H.W. Sun, W.T. Watford, H. Takatori, H.L. Ramos, H. Takahashi, J. Liang, G. Gutierrez-Cruz, C. Zang, W. Peng, J.J. O’Shea, and Y. Kanno. 2010. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity 32 (6): 840–851.

44. Thieu, V.T., Q. Yu, H.C. Chang, N. Yeh, E.T. Nguyen, S. Sehra, and M.H. Kaplan. 2008. Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. Immunity 29 (5): 679–690.

45. Karamouzis, M.V., P.A. Konstantinopoulos, and A.G. Papavassiliou. 2007. The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics. Journal of Molecular Medicine (Berlin, Germany) 85 (5): 427–436.

46. Li, Y., H. Du, Y. Qin, J. Roberts, O.W. Cummings, and C. Yan. 2007. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Research 67 (18): 8494–8503.

47. Meyer, T., and U. Vinkemeier. 2007. STAT nuclear translocation: potential for pharmacological intervention. Expert Opinion on Therapeutic Targets 11 (10): 1355–1365.

48. Chittezhath, M., G. Deep, R.P. Singh, C. Agarwal, and R. Agarwal. 2008. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Molecular Cancer Therapeutics. 7 (7): 1817–1826.